Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 2 , Pages 277-305 , June 2007

Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination

  • Samuel Refetoff, MD (Professor of Medicine, Pediatrics, Molecular Medicine and Genetics)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Medicine, University of Chicago, MC 3090, 5841 S. Maryland Avenue, Chicago, IL 60637, USA. Tel.: +1 773 702 6939; Fax: +1 773 702 6940.

References 

  1. Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stippled epiphyses, goiter, and abnormally high PBI: possible target organ refractoriness to thyroid hormone. The Journal of Clinical Endocrinology and Metabolism. 1967;27:279–294
  2. Refetoff S, DeGroot LJ, Benard B, et al. Studies of a sibship with apparent hereditary resistance to the intracellular action of thyroid hormone. Metabolism. 1972;21:723–756
  3. Sakurai A, Takeda K, Ain K, et al. Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor b. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:8977–8981
  4. Usala SJ, Tennyson GE, Bale AE, et al. A base mutation of the c-erbAb thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds. The Journal of Clinical Investigation. 1990;85:93–100
  5. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocrine Reviews. 1993;14:348–399
  6. Dumitrescu AM, Liao XH, Best TB, et al. A Novel Syndrome Combining Thyroid and Neurological Abnormalities Is Associated with Mutations in a Monocarboxylate Transporter Gene. American Journal of Human Genetics. 2004;74:168–175
  7. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004;364:1435–1437
  8. Dumitrescu AM, Liao X-H, Abdullah SYM, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nature Genetics. 2005;37:1247–1252
  9. Friesema EC, Jansen J, Milici C, et al. Thyroid hormone transporters. Vitamins and Hormones. 2005;70:137–167
  10. Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews. 2002;23:38–89
  11. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Molecular and Cellular Endocrinology. 2003;213:1–11
  12. Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annual Review of Physiology. 2000;62:439–466
  13. Yen PM, Ando S, Feng X, et al. Thyroid hormone action at the cellular, genomic and target gene levels. Molecular and Cellular Endocrinology. 2006;246:121–127
  14. Dumitrescu AM, Liao XH, Weiss RE, et al. Tissue specific thyroid hormone deprivation and excess in Mct8 deficient mice. Endocrinology. 2006;4036–4043
  15. Fondell JD, Guermah M, Malik S, et al. Thyroid hormone receptor-associated proteins and general positive cofactors mediate thyroid hormone receptor function in the absence of the TATA box-binding protein-associated factors of TFIID. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:1959–1964
  16. Beck-Peccoz P, Chatterjee VKK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid. 1994;4:225–232
  17. Weiss RE, Weinberg M, Refetoff S. Identical mutations in unrelated families with generalized resistance to thyroid hormone occur in cytosine-guanine-rich areas of the thyroid hormone receptor beta gene: Analysis of 15 families. The Journal of Clinical Investigation. 1993;91:2408–2415
  18. Weiss RE, Marcocci C, Bruno-Bossio G, et al. Multiple genetic factors in the heterogeneity of thyroid hormone resistance. The Journal of Clinical Endocrinology and Metabolism. 1993;76:257–259
  19. Mixson AJ, Hauser P, Tennyson G, et al. Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone. The Journal of Clinical Investigation. 1993;91:2296–2300
  20. Hayashi Y, Janssen OE, Weiss RE, et al. The relative expression of mutant and normal thyroid hormone receptor genes in patients with generalized resistance to thyroid hormone determined by estimation of their specific messenger ribonucleic acid products. The Journal of Clinical Endocrinology and Metabolism. 1993;76:64–69
  21. Sadow P, Reutrakul S, Weiss RE, et al. Resistnace to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes. Current Opinion in Endocrinology and Diabetes. 2000;7:253–259
  22. Weiss RE, Hayashi Y, Nagaya T, et al. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptors a or ß genes may be due to a defective co-factor. The Journal of Clinical Endocrinology and Metabolism. 1996;81:4196–4203
  23. LaFranchi SH, Snyder DB, Sesser DE, et al. Follow-up of newborns with elevated screening T4 concentrations. The Journal of Pediatrics. 2003;143:296–301
  24. Takeda K, Sakurai A, DeGroot LJ, et al. Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-ß gene. JThe Journal of Clinical Endocrinology and Metabolism. 1992;74:49–55
  25. Mitsuhashi T, Tennyson GE, Nikodem VM. Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormones. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:5804–5805
  26. Macchia PE, Takeuchi Y, Kawai T, et al. Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:349–354
  27. Chassande O, Fraichard A, Gauthier K, et al. Identification of transcripts initiated from an internal promoter in the c-erb-Aa locus that encode inhibitors of retinoic acid receptor-a and triiodothyronine receptor activities. Molecular Endocrinology (Baltimore, Md.). 1997;11:1278–1290
  28. Williams GR. Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Molecular and Cellular Biology. 2000;20:8329–8342
  29. Gauthier K, Plateroti M, Harvey CB, et al. Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Molecular and Cellular Biology. 2001;21:4748–4760
  30. Gauthier K, Chassande O, Platerotti M, et al. Different functions for the thyroid hormone receptors TRα and TRβ in the control of thyroid hormone production and post-natal development. The Embo Journal. 1999;18:623–631
  31. Göthe S, Wang Z, Ng L, et al. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes & Development. 1999;13:1329–1341
  32. Adams M, Matthews C, Collingwood TN, et al. Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone: identification of thirteen novel mutations in the thyroid hormone receptor ß gene. The Journal of Clinical Investigation. 1994;94:506–515
  33. Collingwood TN, Wagner R, Matthews CH, et al. A role for helix 3 of the TRß ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone. The Embo Journal. 1998;17:4760–4770
  34. Feng W, Ribeiro RCJ, Wagner RL, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 1998;280:1747–1749
  35. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454–457
  36. Hörlein AJ, Näär AM, Heinzel T, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995;377:397–404
  37. Busch K, Martin B, Baniahmad A, et al. At least three subdomains of v-erbA are involved in its silencing function. Molecular Endocrinology (Baltimore, Md.). 1997;11:379–389
  38. Forman BM, Samuels HH. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Molecular Endocrinology (Baltimore, Md.). 1990;4:1293–1301
  39. Kurokawa R, Yu VC, Naar A, et al. Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes & Development. 1993;7:1423–1435
  40. Au-Fliegner M, Helmer E, Casanova J, et al. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Molecular and Cellular Endocrinology. 1993;13:5725–5737
  41. Beck-Peccoz P, Chatterjee VKK, Chin WW, et al. Nomenclature of thyroid hormone receptor ß-gene mutations in resistance to thyroid hormone: Consensus statement from the first workshop on thyroid hormone resistance, July 10-11, 1993, Cambridge, United Kingdom. The Journal of Clinical Endocrinology and Metabolism. 1993;78:990–993
  42. Tone Y, Collingwood TN, Adams M, et al. Functional analysis of a transactivation domain in the thyroid hormone ß receptor. The Journal of Biological Chemistry. 1994;269:31157–31161
  43. Baniahmad A, Leng X, Burris TP, et al. The t4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Molecular and Cellular Biology. 1995;15:76–86
  44. Hamy F, Helbeque NJ, Henichart P. Comparison between synthetic nuclear localisation signal peptides from the steroid thyroid hormone receptor superfamily. Biochemical and Biophysical Research Communications. 1992;183:289–293
  45. Wurtz J-M, Bourguet W, Renaud J-P, et al. A canonical strusture for the ligand-binding domain of the nuclear receptors. Nature Structural Biology. 1996;3:87–94
  46. Hayashi Y, Weiss RE, Sarne DH, et al. Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-ß receptors?. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3246–3256
  47. Yoh SM, Chatterjee VKK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptor and transcriptional corepressor. Molecular Endocrinology (Baltimore, Md.). 1997;11:470–480
  48. Gottlieb B, Lehvaslaiho H, Beitel LK, et al. The androgen receptor gene mutations database. Nucleic Acids Research. 1998;26:234–238
  49. Ando S, Sarlis NJ, Oldfield EH, et al. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. The Journal of Clinical Endocrinology and Metabolism. 2001;86:5572–5576
  50. Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health prospective study. Annals of Internal Medicine. 1995;123:573–583
  51. Ono S, Schwartz ID, Mueller OT, et al. Homozygosity for a ‘dominant negative’ thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. The Journal of Clinical Endocrinology and Metabolism. 1991;73:990–994
  52. Persani L, Asteria C, Tonacchera M, et al. Evidence for secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance. The Journal of Clinical Endocrinology and Metabolism. 1994;78:1034–1039
  53. Hayashi Y, Sunthornthepvarakul T, Refetoff S. Mutations of CpG dinucleotides located in the triiodothyronine (T3)-binding domain of the thyroid hormone receptor (TR) ß gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid hormone. The Journal of Clinical Investigation. 1994;94:607–615
  54. Yagi H, Pohlenz J, Hayashi Y, et al. Resistance to thyroid hormone caused by two mutant thyroid hormone receptor ß, R243Q and R243 W, with marked impairment of function that cannot be explained by altered in-vitro 3,5,3'-triiodothyronine binding affinity. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1608–1614
  55. Safer JD, Cohen RN, Hollenberg AN, et al. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. The Journal of Biological Chemistry. 1998;273:30175–30182
  56. Clifton-Bligh RJ, de Zegher F, Wagner RL, et al. A novel mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation. Molecular Endocrinology (Baltimore, Md.). 1998;12:609–621
  57. Kurokawa R, DiRenzo J, Boehm M, et al. Regulation of retinoid signaling by receptor polarity and allosteric control of ligand binding. Nature. 1994;371:528–531
  58. Flamant F, Samarut J. Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends in Endocrinology and Metabolism. 2003;14:85–90
  59. Jones I, Srinivas M, Ng L, et al. The thyroid hormone receptor beta gene: structure and functions in the brain and sensory systems. Thyroid. 2003;13:1057–1068
  60. Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor Beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid. 2002;12:963–969
  61. Kaneshige M, Suzuki H, Kaneshige K, et al. A targeted dominant negative mutation of the thyroid hormone alpha 1 receptor causes increased mortality, infertility, and dwarfism in mice. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:15095–15100
  62. Tinnikov A, Nordstrom K, Thoren P, et al. Retardation of post-natal development caused by a negatively acting thyroid hormone receptor alpha1. The Embo Journal. 2002;21:5079–5087
  63. Liu YY, Schultz JJ, Brent GA. A thyroid hormone receptor alpha gene mutation (P398H) Is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice. The Journal of Biological Chemistry. 2003;278:38913–38920
  64. Flamant F, Poguet AL, Plateroti M, et al. Congenital Hypothyroid Pax8(-/-) Mutant Mice Can Be Rescued by Inactivating the TRalpha Gene. Molecular Endocrinology (Baltimore, Md.). 2002;16:24–32
  65. Morte B, Manzano J, Scanlan T, et al. Deletion of the thyroid hormone receptor alpha 1 prevents the structural alterations of the cerebellum induced by hypothyroidism. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:3985–3989
  66. Weiss RE, Xu J, Ning G, et al. Mice deficient in the steroid receptor coactivator-1 (SRC-1) are resistant to thyroid hormone. The Embo Journal. 1999;18:1900–1904
  67. Brown NS, Smart A, Sharma V, et al. Thyroid hormone resistance and increased metabolic rate in the RXR-g-deficient mouse. The Journal of Clinical Investigation. 2000;106:73–79
  68. Wu SY, Cohen RN, Simsek E, et al. A novel thyroid Hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone. The Journal of Clinical Endocrinology and Metabolism. 2006;91:1887–1895
  69. Anselmo J, Cao D, Karrison T, et al. Fetal loss associated with excess thyroid hormone exposure. The Journal of the American Medical Association. 2004;292:691–695
  70. Weiss RE, Refetoff S. Editorial: treatment of resistance to thyroid hormone-primum non nocere. The Journal of Clinical Endocrinology and Metabolism. 1999;84:401–404
  71. Anselmo J, Refetoff S. Regression of a large goiter in a patient with resistance to thyroid hormone by every other day treatment with triiodothyronine. Thyroid. 2004;14:71–74
  72. Ekins R. The free hormone hypothesis and measurement of free hormones. Clinical Chemistry. 1992;38:1289–1293
  73. Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocrine Reviews. 2001;22:451–476
  74. Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly. American Journal of Mental Deficiency. 1944;48:325–334
  75. Schwartz CE, Ulmer J, Brown A, et al. Allan-Herndon syndrome. II. Linkage to DNA markers in Xq21. American Journal of Human Genetics. 1990;47:454–458
  76. Schwartz CE, May MM, Carpenter NJ, et al. Allan-Herndon-Dudley Syndrome and the Monocarboxylate Transporter 8 (MCT8) Gene. American Journal of Human Genetics. 2005;77:41–53
  77. Lafreniere RG, Carrel L, Willard HF. A novel transmembrane transporter encoded by the XPCT gene in Xq13.2. Human Molecular Genetics. 1994;3:1133–1139
  78. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv. 2004;447:619–628
  79. Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. The Journal of Biological Chemistry. 2003;
  80. Kakinuma H, Itoh M, Takahashi H. A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid. The Journal of Pediatrics. 2005;147:552–554
  81. Friesema EC, Jansen J, Heuer H, et al. Mechanisms of disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8. Nature Clinical Practice. Endocrinology & Metabolism. 2006;2:512–523
  82. Brockmann K, Dumitrescu AM, Best TT, et al. X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. Journal of Neurology. 2005;252:663–666
  83. Herzovich V, Vaiani E, Marino R, et al. Unexpected peripheral markers of thyroid function in a patient with a novel mutation of the MCT8 thyroid hormone transporter gene. Hormone Research. 2006;67:1–6
  84. Maranduba CM, Friesema EC, Kok F, et al. Decreased cellular T3 uptake and metabolism in Allan-Herndon-Dudley syndrome(AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter. Journal of Medical Genetics. 2006;43:457–460
  85. Holden KR, Zuniga OF, May MM, et al. X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype. Journal of Child Neurology. 2005;20:852–857
  86. Dumitrescu A, Liao X-H, Lado-Abeal J, et al. On the mechanism producing the unusual thyroid phenotype in defects of the MCT8 gene. Thyroid. 2004;14:761;(abstract)
  87. Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. The Journal of Clinical Investigationt. 2007;117:627–635
  88. Bernal J. Role of monocarboxylate anion transporter 8 (MCT8) in thyroid hormone transport: answers from mice. Endocrinology. 2006;147:4034–4035
  89. Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid. 2005;15:835–840
  90. Lescure A, Allmang C, Yamada K, et al. cDNA cloning, expression pattern and RNA binding analysis of human selenocysteine insertion sequence (SECIS) binding protein 2. Gene. 2002;291:279–285
  91. Copeland PR. Regulation of gene expression by stop codon recoding: selenocysteine. Gene. 2003;312:17–25
  92. Köhrle J. Selenium and the control of thyroid hormone metabolism. Thyroid. 2005;15:841–853
  93. Schneider MJ, Fiering SN, Pallud SE, et al. Targeted Disruption of the Type 2 Selenodeiodinase Gene (DIO2) Results in a Phenotype of Pituitary Resistance to T(4). Molecular Endocrinology (Baltimore, Md.). 2001;15:2137–2148
  94. Bosl MR, Takaku K, Oshima M, et al. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proceedings of the National Academy of Sciences of the United States of America. 1997;94:5531–5534
  95. Schneider MJ, Fiering SN, Thai B, et al. Targeted disruption of the type 1 selenodeiodinase gene (dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology. 2006;147:580–589
  96. Hernandez A, Martinez ME, Fiering S, et al. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. The Journal of clinical investigation. 2006;116:476–484
  97. Maia AL, Berry MJ, Sabbag R, et al. Structural and functional differences in the dio1 gene in mice with inherited type 1 deiodinase deficiency. Molecular Endocrinology (Baltimore, Md.). 1995;9:969–980
  98. Ng L, Goodyear RJ, Woods CA, et al. Hearing loss and retarded cochlear development in mice lacking type 2 iodothyronine deiodinase. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:3474–3479
  99. Carlson BA, Xu XM, Gladyshev VN, et al. Selective rescue of selenoprotein expression in mice lacking a highly specialized methyl group in selenocysteine tRNA. The Journal of Biological Chemistry. 2005;280:5542–5548
  100. Chu FF, Esworthy RS, Chu PG, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Research. 2004;64:962–968

PII: S1521-690X(07)00026-7

doi: 10.1016/j.beem.2007.03.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 2 , Pages 277-305 , June 2007

Article Tools

* Image Usage & Resolution